Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeuroEXPLORER [18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease
2024-515636-77-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Mar 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 18F-AlF-NOTA-octreotide in Carotid artery disease (CAD), sponsored by UZ Leuven. Planned start Mar 2025; status: authorised.
02
Drugs
18F-AlF-NOTA-octreotide
03
Conditions
Carotid artery disease (CAD)
Beyond the preview
Go deeper on 2024-515636-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515636-77-00.